# Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

> **NCT04043897** · PHASE2 · RECRUITING · sponsor: **Eugene F Yen, MD** · enrollment: 10 (estimated)

## Conditions studied

- Microscopic Colitis

## Interventions

- **DRUG:** Rifaximin 550mg

## Key facts

- **NCT ID:** NCT04043897
- **Lead sponsor:** Eugene F Yen, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-06-29
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04043897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04043897, "Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04043897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*